Avanos Medical shows resilient fundamentals - a four-quarter beat streak, strong Piotroski quality score, and positive free cash flow - but technical momentum has failed the engine's threshold and the stock's upside looks exhausted near its 52-week high, supporting a hold rather than an add.
Thesis pillars
- Strong Piotroski Cash Conversion→Stable
- Earnings Beat Streak→Stable
- Momentum Gate Failure→Stable
- +2 more pillars — see the Why tab for full reasoning
Avanos Medical, Inc. (AVNS) Stock Analysis
Range Bound setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $24.92, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: Mexico manufacturing; Concentration risk — Supplier: sole suppliers.
Avanos Medical is a medical device company operating in two segments: Specialty Nutrition Systems (enteral feeding products including MIC-KEY, Corpak, and NeoMed) and Pain Management and Recovery (non-opioid solutions including ON-Q, COOLIEF, and Game Ready). It sells to... Read more
Hold if already holding. Not a fresh buy at $24.92, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: Mexico manufacturing; Concentration risk — Supplier: sole suppliers. Chart setup: RSI 48 mid-range, Bollinger mid-band. Mixed signals. Hold existing position. Score 5.9/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About Avanos Medical, Inc.
About Avanos Medical, Inc.
Avanos Medical sells enteral feeding devices such as MIC-KEY, Corpak, and NeoMed alongside non-opioid pain-management products including ON-Q, COOLIEF, and Game Ready, organized into two segments: Specialty Nutrition Systems and Pain Management and Recovery. Sales to Medline Industries accounted for approximately 12% of Avanos's consolidated net sales in 2025, and the company manufactures the majority of its output at two facilities in Mexico, supplementing production in the United States and Canada.
Avanos earns revenue by selling directly to hospitals and ambulatory care centers and through third-party wholesale distributors, which handled approximately 49% of North American net sales and 67% of sales outside North America in 2025; roughly 29% of global net sales were contracted through group purchasing organizations, to which Avanos pays a fee recorded as a reduction of net sales. The company spent $23.3 million on research and development in 2025, down from $27.2 million in 2023, as it worked through a multi-year Transformation Process begun in January 2023 that combined its Chronic Care and Pain Management franchises, divested the Respiratory Health business for $110.0 million in 2023, and sold its HA product line and Game Ready rental business in 2025. In September 2025, Avanos acquired vascular-access device maker Nexus Medical for $27.0 million plus up to $20.0 million in contingent consideration, expanding beyond its historical call points in nutrition and pain management.
Show full overview
Avanos concentrates the majority of its manufacturing output at two facilities in Mexico, and separately discloses that it purchases certain components and raw materials from sole suppliers for quality and cost reasons, leaving limited near-term alternatives if either concentration is disrupted. The 10-K flags a specific, dated version of this risk: potential U.S. military action against drug cartels in Mexico could disrupt political and economic relations between the two countries and adversely affect Avanos's Mexican manufacturing operations. Separately, a group of Medicare Administrative Contractors has drafted a proposed policy questioning coverage for radiofrequency ablation treatment of peripheral nerve pain, with a final determination expected in early 2026 that could eliminate Medicare reimbursement for Avanos's RFA-based pain products in the affected regions.
See also: Healthcare · Medical Devices
From Avanos Medical, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-08Recent Developments — Avanos Medical, Inc.
Latest news
- NEWS Avanos Medical And American Industrial Partners Obtain Required Regulatory Approvals For Pending Merger — benzinga Jul 2, 2026 positive
Generated 2026-07-08T23:14:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWCustomerMedline Industries12%10-K Item 1: 'In the year ended December 31, 2025, sales to Medline Industries accounted for approximately 12% of consolidated net sales.'
- HIGHGeographicMexico manufacturing10-K Item 1A: 'the majority of our manufacturing output is concentrated at the two manufacturing facilities that we operate in Mexico'
- HIGHSuppliersole suppliers10-K Item 1A: 'for quality assurance or cost effectiveness, we purchase from sole suppliers certain components and raw materials'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $24.92, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: Mexico manufacturing; Concentration risk — Supplier: sole suppliers. Chart setup: RSI 48 mid-range, Bollinger mid-band. Mixed signals. Hold existing position. Target $24.58 (-1.4%), stop $24.72 (−0.8%), A.R:R 0.0:1. Score 5.9/10, moderate confidence.
Take-profit target: $24.58 (-1.4% upside). Target $24.58 (-1.4%), stop $24.72 (−0.8%), A.R:R 0.0:1. Stop-loss: $24.72.
Concentration risk — Geographic: Mexico manufacturing; Concentration risk — Supplier: sole suppliers; Near 52-week high (2.2% away).
Avanos Medical, Inc. trades at a P/E of N/A (forward 19.9). TrendMatrix value score: 6.8/10. Verdict: Hold.
6 analysts cover AVNS with a consensus score of 2.2/5.
What does Avanos Medical, Inc. do?Avanos Medical is a medical device company operating in two segments: Specialty Nutrition Systems (enteral feeding...
Avanos Medical is a medical device company operating in two segments: Specialty Nutrition Systems (enteral feeding products including MIC-KEY, Corpak, and NeoMed) and Pain Management and Recovery (non-opioid solutions including ON-Q, COOLIEF, and Game Ready). It sells to hospitals and ambulatory care centers worldwide through distributors and group purchasing organizations, and completed the $27.0 million Nexus Medical acquisition in September 2025 to expand into vascular access.